Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease

(2011) J. L. M. Ferrara et al.   BLOOD

Prognostic value of response after upfront therapy for acute GVHD

(2011) R M Saliba et al.   BONE MARROW TRANSPLANTATION

Graft-versus-Host Disease Treatment: Predictors of Survival

(2010) John E. Levine et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The best endpoint for acute GVHD treatment trials

(2010) M. L. MacMillan et al.   BLOOD

Graft-versus-host disease: proteomics comes of age

(2009) G. Socie   BLOOD

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

(2009) A. M. Alousi et al.   BLOOD

Graft-versus-host disease

(2009) James LM Ferrara et al.   LANCET

A biomarker panel for acute graft-versus-host disease

(2008) S. Paczesny et al.   BLOOD

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

(2008) C. M. Sturgeon et al.   CLINICAL CHEMISTRY